December 22, 2021 5:26pm
As I wrote, “Sector stock’s rise, stock’s fall – forget the sector and market, focus on the Christmas holiday coming”
Pre-open indication results: 5 HITs, 1 MISS
If I have learned one thing as a former research analyst, venture and public markets investor to a journalist; it is that your life and your bank account are largely tied to your questioning of price movements and targets.
Who else is tracking a broad representative of cell and gene therapy equities – with facts supported by real numbers?
The Dow closed UP +261.19 points (+0.74%); the S&P closed UP +47.33 points (+1.02%) while the Nasdaq closed UP +180.81 points (+1.18%)
Indexes rose on Wednesday, rallying for a second day as the market continued to rebound from a three-day losing streak spurred by fears about the omicron Covid variant.
December, normally the calmest month for markets, has so far been the most volatile month of 2021 …
Note: The FDA on Wednesday granted emergency use authorization for Pfizer’s (PFE) Covid pill, the first antiviral drug against the virus for at-home use with the share price gaining +0.60 or +1.02%.
RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …
- Wednesday opened negative at 8 up/24 downs, 2 flats and 1 acquired, flipped positive at the mid-day at 18/16 and 1 acquired, ending with a barely positive close of 17/16, 1 flat, and 1 acquired;
- Tuesday opened positive at 25 up/6 downs, 3 flats and 1 acquired, flipped negative at the mid-day at 13/19, 2 flats and 1 acquired, ending with a positive close of 20/9, 5 flats, and 1 acquired;
- Monday opened negative at 1 up/32 downs, 2 flat and 1 acquired, flipped positive at the mid-day at 18/15, 1 flat and 1 acquired, ending with a neutral close of 16/16, 2 flats, and 1 acquired;
RegMed Investors’ (RMi) pre-open: “Merry Christmas coming, it’s time to be finished with portfolio timing. Sector stock’s rise, stock’s fall – forget the market, focus on the Christmas holiday coming” … https://www.regmedinvestors.com/articles/12237
Pre-open indication results: 5 HITs: < SELL into Strength Fate Therapeutics (FATE +$0.80), bluebird bio (BLUE -$0.46), Vericel (VCEL +$0.62), ReNeuron (RENE.L +$3.00); BUY: Intellia Therapeutics (NTLA +$0.01)> and 1 MISS: < Biostage (OTCQB: BSTG +$0.06)>
Key Metric - volume
Sector volume INCREASED with 5 of the 17-upside having higher than the 3-month average volume with INCREASED volume of 4 of 16-downside having higher than the 3-month average volume;
Note: Biostage (BSTG) closed up +$0.0625 with 1,360 shares traded after Tuesday’s -$0.49 with 4,582 shares traded to $2.48, Monday’s +$0.53 with 425 shares traded, Friday’s -$0.37 on Friday with 5,734 shares traded, Thursday’s flat with 371 shares traded and last Wednesday’s flat with 3,281 shares traded. Has he, David Green, the new interim CEO and chairman CONDONED the “pump and promote”?
Jumping with share pricing momentum (10 of 17):
- ReNeuron (RENE.L +$3.00),
- CRISPR Therapeutics (CRSP +$1.64 after Tuesday’s -$1.13 and Monday’s -$1.68),
- BioLife Solutions (BLFS +$1.16 after Tuesday’s +$1.53 and Monday’s +$0.17),
- Sage Therapeutics (SAGE +$0.91 after Tuesday’s -$0.28 and Monday’s -$0.20),
- Fate Therapeutics (FATE +$0.80 after Tuesday’s +$3.18 and Monday’s +$1.36),
- Vericel (VCEL +$0.62 after Tuesday’s +$2.55 and Monday’s -$2.52),
- Chinook Therapeutics (KDNY +$0.38 after Tuesday’s +$0.55 and Monday’s -$0.10),
- AxoGen (AXGN +$0.34),
- Regenxbio (RGNX +$0.20 after Tuesday’s +$1.16 and Monday’s +$0.46),
- Mesoblast (MESO +$0.16),
Hammered in today’s market (10 of 16):
- Alnylam Pharmaceuticals (ALNY -$12.21 after Tuesday’s +$1.30 and Monday’s +$3.72),
- Ultragenyx (RARE -$2.19),
- bluebird bio (BLUE -$0.46 after Tuesday’s +$0.87 and Monday’s -$0.09),
- Ionis Pharmaceuticals (IONS -$0.30 after Tuesday’s +$0.42 and Monday’s -$0.25)
- Editas Medicine (EDIT -$0.28 after Tuesday’s -$0.38 and Monday’s +$0.32),
- Pluristem (PSTI -$0.12),
- Bellicum Pharmaceuticals (BLCM -$0.10 after Tuesday’s -$0.02)
- Global Blood Therapeutics (GBT -$0.07 after Tuesday’s -$0.12 and Monday’s +$0.71),
- Voyager Therapeutics (VYGR -$0.05),
- Solid Biosciences (SLDB -$0.04),
- 1- Verastem (VSTM) and 1- Stemline Therapeutics (STML) – acquired
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Wednesday, the IBB closed down -0.12% and XBI closed down -0.05%
- Tuesday, the IBB closed up +0.61% and XBI closed up +0.68%
- Monday the IBB closed down -0.94% and XBI closed up +0.18%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Wednesday was down -2.38 points or -11.33% at 18.63
- Tuesday was down -1.86 points or -8.13% at 21.01
- Monday was up +1.30 points or + 6.03% at 22.87
December, the second month of Q4/21:
Wednesday closed positive with 17 incliners, 16 decliners 1 flat and 1 acquired
Tuesday closed positive with 20 incliner, 9 decliners, 5 flat and 1 acquired
Monday (12/20) closed neutral with 16 incliner, 16 decliners, 2 flats and 1 acquired
Friday closed positive with 27 incliner, 7 decliners and 1 acquired
Thursday closed negative with 3 incliners, 30 decliners, 1 flat and 1 acquired
Wednesday closed positive with 27 incliners, 6 decliners 1 flat and 1 acquired
Tuesday closed negative with 7 incliners, 27 decliners and 1 acquired
Monday (12/13) closed positive with 16 incliner, 15 decliners, 3 flats and 1 acquired
Friday closed negative with 8 incliner, 25 decliners, 1 flat and 1 acquired
Thursday closed negative with 0 incliners, 33 decliners, 1 flat and 1 acquired
Wednesday closed positive with 24 incliners, 7 decliners, 3 flats and 1 acquired
Tuesday closed positive with 29 incliner, 4 decliners, 1 flat and 1 acquired
Monday (12/6) closed positive with 25 incliner, 9 decliners and 1 acquired
Friday closed negative with 1 incliner, 31 decliners, 2 flats and 1 acquired
Thursday closed positive with 26 incliners, 8 decliners and 1 acquired
Wednesday (12/1) closed negative with 4 incliners, 29 decliners, 1 flat and 1 acquired
The BOTTOM LINE: Let’s go to the holiday with peace and disregard for market’s forces.
The market is under pressure and the sector is just responding to algorithmic moves. Although Tuesday's rally was a positive step, the cell and gene therapy sector show a hair more strength on Wednesday.
The biggest risk for the sector is a spike in volatility, which makes it difficult to sustain market direction.
Biggest gainers today were: ReNeuron (RENE.L), CRISPR Therapeutics (CRSP), and Sage Therapeutics (SAGE) – each with low volume while the biggest losers today were: Alnylam Pharmaceuticals (ALNY), Ultragenyx (RARE) and Intellia Therapeutics (NTLA) – two (2) of three (3) had low volume.
Be aware: Athersys (ATHX) and Caladrius Biosciences (CLBS) were trading under the Nasdaq $1.00 “listing number”.
Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”
I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”
WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.